Laguna Bio published a new article on the latest evolution of its R&D program on co-stimulatory signals.
Public source
Publisher name
Public post
Evolution has been running this R&D program for millions of years. We're still stuck on one co-stimulatory signal. Check out the latest Laguna Beacon article from our CE…
Company
Laguna Bio
Laguna Bio is perfecting a novel approach to selectively activate and expand the immune system against cancer.
- Industry
- Biotechnology Research
- Location
- Berkeley, US
- Company size
- 2–10 employees
About Laguna Bio
Supercharging immunotherapy
See moreLatest activity
Latest activity from Laguna Bio
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Rondo Therapeutics
Rondo Therapeutics believes innovation in co-stimulatory bispecific antibodies represents an exciting frontier in immuno-oncology.
Research & Knowledge
ImmunityBio, Inc.
ImmunityBio, Inc. researchers continue working to develop new treatment options for women facing ovarian cancer.
Research & Knowledge
Nouscom
Nouscom published Phase 1b/2 data in NatureMedicine.
Research & Knowledge
Bio X Cell
Bio X Cell published an application highlight exploring complementary perturbation strategies in combination immunotherapy studies to distinguish cellular drivers of therapeutic response and strengthen mechanistic interpretation.
Research & Knowledge
TQ Therapeutics